Recent Updates
Recently added Catalysts

hMaxi-K

Phase 2

Erectile Dysfunction | Small Molecules | Endocrine |Roivant Sciences Ltd.|Trials Updated: Apr 20, 2023

hMaxi-K development status

Highest phase Phase 2
Registered trials 3 across 1 sponsor since Dec 2019

hMaxi-K target and mechanism

ModalitySmall Molecules

Also known as URO-902

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials3
Total Enrollment119

FDA Designations

No designations recorded

hMaxi-K clinical trials

hMaxi-K · 3 trials · 3 indications

Phase 2 2Phase 1 1
NCT02713789Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for EDErectile Dysfunction
COMPLETED26 Analytics
NCT04211831URO-902 in Female Subjects With Overactive Bladder and Urge Urinary IncontinenceOveractive Bladder With Urge Urinary Incontinence
COMPLETED80 Analytics
PHASE2COMPLETED
Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for ED
Erectile DysfunctionUnlock trial analytics
PHASE2COMPLETED
URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
Overactive Bladder With Urge Urinary IncontinenceUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Adverse Experiences as Measured by Changes in Physical Examination of the Penis
up to Week 24 ± 3 days

Physical examination of the penis included inspection and palpation.

Number of Participants With Significant Changes in Clinical Laboratory Parameters as Measured on Interval Blood and Urine Tests
up to Week 24 ± 3 days

Clinical significance was determined by the Investigator using central laboratory values.

Number of Participants With Significant Changes on the Cardiogram as Measured by Significant Prolongation of QT Intervals and Cardiac Rhythm
up to Week 24 ± 3 days

Clinical significance was determined by the Investigator using central laboratory values.

Change From Baseline at Week 12 in Average Daily Number of Urgency Episodes
Baseline (Day 1) and at Week 12

Average daily number of urgency episodes was calculated as the total number of urgency episodes recorded on a completed diary day within the visit window divided by the number of days the Bladder Diary was filled out. An urgency episode was defined as when a participant answered "Yes" to the question "Need to urinate immediately" on the bladder diary electronic case report form (eCRF). If a participant had more than 1 bladder diary filled out on the same day, then all the urgency episodes were summed together. The denominator used for calculating the average number only counted the days in which there was at least 1 completed bladder diary day within the visit window. Baseline was defined as the last non-missing measurement prior to the study treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Number of participants with any treatment-emergent adverse event during the Treatment Period
6 months (24 weeks) per participant
Number of participants with any treatment-emergent adverse event during the Safety Follow-up Period
18 months
Number of participants with any clinically significant clinical laboratory test value during the Treatment Period
6 months (24 weeks) per participant
Number of participants with any clinically significant clinical laboratory test value during the Safety Follow-up Period
18 months
Number of participants with any clinically significant electrocardiogram finding during the Treatment Period
6 months (24 weeks) per participant
Number of participants with any clinically significant electrocardiogram finding during the Safety Follow-up Period
18 months
Number of participants with any clinically significant physical examination finding during the Treatment Period
6 months (24 weeks) per participant
Number of participants with any clinically significant physical examination finding during the Safety Follow-up Period
18 months

Secondary Endpoints

Mean Change From Baseline in the Percentage of "Yes" Responses to Questions 2 and 3 of the Sexual Encounter Profile (SEP) at Week 24
Baseline; Week 24
Change From Baseline in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF) at Week 24
Baseline; Week 24
Change From Baseline in the Orgasmic Function Domain of the International Index of Erectile Function (IIEF) at Week 24
Baseline; Week 24
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeOTHER

Treatment Arms

ArmTypeDescription
hMaxi-KACTIVE_COMPARATORSingle Treatment/ two escalating dose levels (8000 µg and 16,000 µg injection). In each dose level, 11 participants will receive hMaxi-K and 6 will receive placebo (only one injection per each participant)
Placebo (PBS-20% sucrose)PLACEBO_COMPARATORPBS-20% sucrose administered during two single treatment dose levels (8000 µg and 16000 µg) by injection (only one injection per each participant)
Cohort 1: URO-902 24 mg; PlaceboEXPERIMENTALParticipants will receive either a single treatment of URO-902 24 milligrams (mg) or matching placebo.
Cohort 2: URO-902 48 mg; PlaceboEXPERIMENTALParticipants will receive either a single treatment of URO-902 48 mg or matching placebo.
hMaxi-K 16000 µgEXPERIMENTALSingle treatment (16000 µg by 20 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.
hMaxi-K 24000 µgEXPERIMENTALSingle treatment (24000 µg by 30 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.

Interventions

NameTypeDescription
hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)DRUG -
Placebo (PBS-20% sucrose)DRUG -
URO-902DRUGintradetrusor injection
PlaceboDRUGintradetrusor injection
hMaxi-KDRUGSingle treatment/2 escalating dose levels (16000 µg and 24000 µg by intramuscular injection)
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 80 Years
SexMALE
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Eligible participants must meet the following inclusion criteria: 1. Signed Informed Consent 2. Be adult males over 18 years of age diagnosed with erectile dysfunction and whose ED is attributable to an underlying, stable medical condition such as hypertension and atheros...

Countries:KuwaitUnited States
Unlock Eligibility Criteria

Frequently asked questions about hMaxi-K

What is hMaxi-K used for?

hMaxi-K is being developed for erectile dysfunction and overactive bladder. It has been studied in a Phase 2A trial in men with erectile dysfunction and a Phase 1 study in women with overactive bladder. It is an investigational gene therapy and has not been approved for any indication.

Who is developing hMaxi-K?

hMaxi-K is being developed by Roivant Sciences Ltd., which trades on the Nasdaq under the ticker ROIV. The company is responsible for the clinical development program, including the completed Phase 2A trial in erectile dysfunction and the Phase 1 study in overactive bladder.

What phase is hMaxi-K in?

hMaxi-K is in Phase 2 development. A Phase 2A clinical trial in erectile dysfunction has been completed, and a Phase 1 study in overactive bladder has also been completed. There are currently no active trials listed for hMaxi-K.

What clinical trials is hMaxi-K in?

hMaxi-K has been studied in two completed clinical trials: NCT02713789, a Phase 2A trial in erectile dysfunction that enrolled 26 men in Kuwait, and NCT01870037, a Phase 1 study in overactive bladder that enrolled 13 women in the United States. Both trials are completed.